NCT06621420|Unknown
Peyronie Disease Questionnaire (PDQ): Turkish Validation
Turkish PDQ
Loading search results
Turkish PDQ
Sponsor study identifier
observational
60
1 country
1
Study Start
September 1, 2024
Actual (reported)Primary Completion
October 30, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 30, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The purpose of the present study is to translate into the Turkish and a perform a validation of the Turkish version of a PDQ and to ensure the use of Turkish validation of the PDQ in clinical use and studies.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 30, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 1, 2024
Actual (reported)September 4, 2024
Actual (reported)October 1, 2024
Actual (reported)October 30, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 30, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Reliability and usability of the Turkish translation of the PDQ
The scores given by the patients according to the previously proven PDQ scoring will be compared statistically. As a result of this comparison, it will be investigated how consistent and reliable the translation is. The measurement tool in this study is the Peyronie disease questionnaire. The PDQ is a 15-item, self-administered, disease-specific, and multidimensional printed format instrument developed to quantify the psychosexual symptoms of PD. The PDQ includes three scales: "psychological and physical symptoms" (6 items), "penile pain" (3 items), and "symptom bother" (4 scored items and 2 yes/no questions). The "psychological and physical symptom" domain has a 5-level Likert scale ranging from "none" to "very severe." Patients must complete items on the "penile pain" domain thinking about the last 24 h, and a numeric scale ranging from 0 to 10 was used to evaluate its severity. The "symptom bother" domain has a 5-level Likert scale ("not at all bothered," "a little bit bothered,").
From September 2024 to April 2025
Men living in the Marmara region whose native language is Turkish
Acibadem University
Istanbul, Turkey (Türkiye)
Hellstrom WJ, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie's disease: validation of the Peyronie's disease questionnaire. J Urol. 2013 Aug;190(2):627-34. doi: 10.1016/j.juro.2013.01.090. Epub 2013 Jan 31.
Garcia-Gomez B, Martinez-Salamanca JI, Sarquella-Geli J, Justo-Quintas J, Garcia-Rojo E, Fernandez-Pascual E, Ruiz-Castane E, Romero-Otero J. Correction: Peyronie's Disease Questionnaire (PDQ): Spanish translation and validation. Int J Impot Res. 2024 Feb;36(1):102. doi: 10.1038/s41443-023-00734-0. No abstract available.
First Submitted
September 4, 2024
First Posted
October 1, 2024
Study Start
September 1, 2024
Actual (reported)Primary Completion
October 30, 2024
Estimated (date passed)Pilot Study on the Efficacy and Safety of FIBRORESTIL® as an Adjuvant Intralesional Treatment in Patients With Peyronie's Disease Receiving Standard Therapy
Contact the study team to confirm eligibility.
Traunero F, Di Grazia M, Ongaro L, Rizzo M, Cocci A, Verze P, Zucchi A, Cai T, Salame L, Garaffa G, Trombetta C, Liguori G. Validation of the Italian version of the Peyronie's Disease Questionnaire (PDQ). Int J Impot Res. 2024 Sep;36(6):588-591. doi: 10.1038/s41443-023-00792-4. Epub 2023 Nov 17.
Citamak B, Dogan C, Koroglu MS, Baser A, Ozkaptan O, Cubuk A. Turkish Translation, Validation, and Clinical Utilization of the Peyronie's Disease Questionnaire. Arch Esp Urol. 2026 Aug;79(7):1115-1122. doi: 10.56434/j.arch.esp.urol.aeu007.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 30, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
October 1, 2024
Record last verified: 2024-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: